Autologous vs allogeneic: manufacturing models built for scale and speed
Cell therapy developers must weigh the trade-offs between patient-specific (autologous) and donor-derived (allogeneic) approaches when designing scalable manufacturing systems. This discussion highlights practical frameworks for optimizing process efficiency, maintaining product consistency, and accelerating timelines from clinical development to commercial supply.
Key takeaways
-
Compare autologous and allogeneic manufacturing strategies for scale and throughput
-
Explore approaches to maintain product quality across diverse production models
-
Discuss process design considerations that enable faster time to clinic
-
Evaluate operational and facility models that support scalable manufacturing
-
Review strategies for integrating regulatory and quality requirements
